{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:34Z","timestamp":1788844234527,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2026.1920964","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:20Z","timestamp":1788841580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Diagnosis, treatment and prognosis of neuroendocrine neoplasms with a focus on peptide receptor radionuclide therapy (PRRT)"],"prefix":"10.3389","volume":"17","author":[{"given":"Ariadni","family":"Spyroglou","sequence":"first","affiliation":[{"name":"Second Department of Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Holmager","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Copenhagen University Hospital-Rigshospitalet","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystallenia I.","family":"Alexandraki","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00820-y","article-title":"Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification","volume":"34","author":"Asa","year":"2021","journal-title":"Mod Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70174","article-title":"European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids","volume":"38","author":"Baudin","year":"2026","journal-title":"J Neuroendocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf035","article-title":"EndoCompass project: research roadmap for pituitary and neuroendocrine tumor endocrinology","volume":"193","author":"Castano","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"de Herder","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020304","article-title":"The role of somatostatin analogues in the control of diarrhea and flushing as markers of carcinoid syndrome: a systematic review and meta-analysis","volume":"13","author":"Alexandraki","year":"2023","journal-title":"J Pers Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.coemr.2021.05.002","article-title":"Neuroendocrine neoplasms: evolving and future treatments","volume":"19","author":"Spyroglou","year":"2021","journal-title":"Curr Opin Endocr Metab Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13479","article-title":"Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: a consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force","volume":"37","author":"Prasad","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1470-2045(26)00108-7","article-title":"177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial","volume":"27","author":"Baudin","year":"2026","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.P117","article-title":"Pivotal phase III COMPOSE trial to compare lutetium (177Lu) edotreotide with best standard of care in patients with well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors","volume":"90","author":"Capdevila","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030504","article-title":"Predictive and prognostic impact of blood-based inflammatory biomarkers in patients with gastroenteropancreatic neuroendocrine tumors commencing peptide receptor radionuclide therapy","volume":"11","author":"Ohlendorf","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13461","article-title":"Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers","volume":"37","author":"Kong","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1169970","article-title":"Long-term prognostic factors for PRRT in neuroendocrine tumors","volume":"10","author":"Trautwein","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31090416","article-title":"The safety and efficacy of peptide receptor radionuclide therapy for gastro-entero-pancreatic neuroendocrine tumors: a single center experience","volume":"31","author":"Piscopo","year":"2024","journal-title":"Curr Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-025-01305-8","article-title":"Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy","volume":"15","author":"Herr","year":"2025","journal-title":"EJNMMI Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.51821\/89.1.14882","article-title":"Real-world outcomes of [177Lu]Lu-DOTA-TATE peptide receptor radionuclide therapy in patients with metastatic gastroenteropancreatic neuroendocrine tumors: data from a Belgian ENETS Center of Excellence","volume":"89","author":"Lazarenko","year":"2026","journal-title":"Acta Gastroenterol Belg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.116.T1","article-title":"NETTER-3: [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, Grade 1\/2 (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden","volume":"116","author":"Kunz","year":"2025","journal-title":"Endocrine Abstracts"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.116.C26","article-title":"Clinical outcomes following salvage PRRT in patients with metastatic neuroendocrine tumors","volume":"116","author":"Koch","year":"2025","journal-title":"Endocrine Abstracts"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07235-w","article-title":"Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience","volume":"52","author":"Kashyap","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.108.C16","article-title":"Targeted alpha therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors","volume":"108","author":"Strosberg","year":"2024","journal-title":"Endocrine Abstracts"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3091","article-title":"Phase Ib portion of the ACTION-1 phase Ib\/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings","volume":"42","author":"Halperin","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1920964\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:21Z","timestamp":1788841581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1920964\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":29,"alternative-id":["10.3389\/fendo.2026.1920964"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1920964","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1920964"}}